Laura Deming is an early-stage venture capitalist who exclusively invests in the longevity sector. See sector focus and contact routes.
Laura Deming is an early-stage venture capitalist who exclusively invests in the longevity sector, targeting Seed through Series B companies developing therapeutics for age-related diseases with check sizes up to $1 million. Her distinctive thesis treats aging itself as a disease rather than an inevitable biological consequence, focusing on extending healthy human lifespan through drugs, gene editing, and cellular reprogramming. Notable portfolio companies include Unity Biotechnology, which developed senolytic drugs for aging diseases, as well as Precision BioSciences, Navitor Pharmaceuticals, and Metacrine.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in San Francisco when building a target list.
Investors like Laura Deming · Full investor directory · Investor access · Company funding database